ESMO Open最新文献

{"title":"91P Are patients with measurable residual disease (MRD) positive or MRD negative different in baseline DNA methylation signatures in precursor B-cell acute lymphoblastic leukaemia (B-ALL)?","authors":"R. Ramesh , S. Desai , B. Choudhary , P. Ganesan , M. Jayanthi , P. Adole , P. Manivannan , S. Kayal","doi":"10.1016/j.esmoop.2024.103832","DOIUrl":"10.1016/j.esmoop.2024.103832","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103832"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10P Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744","authors":"A. Mokhtar , S. Hany , T. Manie , E. Khallaf , R.A. Youness","doi":"10.1016/j.esmoop.2024.103756","DOIUrl":"10.1016/j.esmoop.2024.103756","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103756"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"85P HDAC6-mediated regulation of progesterone receptor: Implications for hormonal therapy in breast cancer","authors":"W.S. Ramadan , R. Alseksek , S. Mouffak , I.M. Talaat , M. Saber-Ayad , R. El-Awady","doi":"10.1016/j.esmoop.2024.103826","DOIUrl":"10.1016/j.esmoop.2024.103826","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103826"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volumetric measurement to evaluate treatment response to induction chemotherapy on MRI outperformed RECIST guideline in outcome prediction in advanced nasopharyngeal carcinoma","authors":"T.S.A. Kwong ,&nbsp;H.S. Leung ,&nbsp;F.K.F. Mo ,&nbsp;Y.M. Tsang ,&nbsp;L. Lan ,&nbsp;L.M. Wong ,&nbsp;T.Y. So ,&nbsp;E.P. Hui ,&nbsp;B.B.Y. Ma ,&nbsp;A.D. King ,&nbsp;Q.Y.H. Ai","doi":"10.1016/j.esmoop.2024.103933","DOIUrl":"10.1016/j.esmoop.2024.103933","url":null,"abstract":"<div><h3>Background</h3><div>Treatment response evaluated by tumour size change is an important indicator for outcome prediction. Advanced nasopharyngeal carcinoma (adNPC) grows irregularly, and so the unidimensional measurement may not be accurately applied to adNPC for outcome prediction. This study aimed to evaluate values of unidimensional and volumetric measurements for treatment response to induction chemotherapy (IC) for outcome prediction in adNPC and compared the values with that of RECIST 1.1 guideline.</div></div><div><h3>Materials and methods</h3><div>Pre-treatment and post-IC magnetic resonance images (MRIs) from 124 patients with stage III-IVA NPC were retrospectively reviewed. Sums of the maximum unidimensional diameters (D) and volumes of the targeted tumours (primary tumour and two largest metastatic lymph nodes) on the pre- (D_pre and V_pre) and post-IC MRIs (D_post-IC and V_post-IC) and percentage changes in D (Δ D%) and V (ΔV%) between two scans were calculated and correlated with disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS) using Cox regression analysis. Area under the curves (AUCs) of independent measurements and RECIST groups (RECIST response and non-response groups) for predicting disease recurrence, locoregional recurrence, and distant metastases, respectively, were calculated and compared using the DeLong test.</div></div><div><h3>Results</h3><div>Univariable analysis showed correlations between high D_post-IC with poor DFS and DMFS (<em>P</em> &lt; 0.05), but not with LRRFS (<em>P</em> = 0.07); high V_post-IC and low ΔV% (less decrease in volume on post-IC) with poor DFS, LRRFS, and DMFS (<em>P</em> &lt; 0.05); and no correlations between D_pre, ΔD%, and V_pre and the outcomes (<em>P</em> &gt; 0.05). Multivariable analysis showed that ΔV% was the only independent measurement for outcomes (<em>P</em> &lt; 0.05). Compared with RECIST groups, ΔV% of 47.9% (median value) showed a higher AUC for disease recurrence (0.682 versus 0.526, <em>P</em> &lt; 0.01) and for locoregional recurrence (0.782 versus 0.585, <em>P</em> &lt; 0.01), but not for distant metastases (0.593 versus 0.518, <em>P</em> = 0.26).</div></div><div><h3>Conclusions</h3><div>Volumetric measurement to evaluate treatment response to IC outperformed unidimensional measurement and RECIST guideline in outcome prediction in adNPC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103933"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","authors":"Y. Li ,&nbsp;H. Zeng ,&nbsp;C. Qi ,&nbsp;S. Tan ,&nbsp;Q. Huang ,&nbsp;X. Pu ,&nbsp;W. Li ,&nbsp;D. Planchard ,&nbsp;P. Tian","doi":"10.1016/j.esmoop.2024.103935","DOIUrl":"10.1016/j.esmoop.2024.103935","url":null,"abstract":"<div><h3>Background</h3><div>The recommended first-line treatment for advanced epidermal growth factor receptor (<em>EGFR)</em>-mutant non-small-cell lung cancer (NSCLC) patients is EGFR-tyrosine kinase inhibitors (EGFR-TKIs). <em>BRAF</em> alterations have been identified as resistance mechanisms. We aimed to identify features of and subsequent treatment strategies for such patients.</div></div><div><h3>Patients and methods</h3><div>We conducted a systematic literature review of NSCLC patients harboring acquired <em>BRAF</em> alterations. Additionally, <em>BRAF</em>-altered NSCLC patients who progressed from EGFR-TKIs at West China Hospital of Sichuan University were screened. Patient characteristics, treatment options, and outcomes were analyzed.</div></div><div><h3>Results</h3><div>A total of 104 patients were included, 2 of whom came from our center. Seventy-five patients (72.1%) harbored <em>BRAF</em> mutations (57 class I mutations, 7 class II mutations, 9 class III mutations, and 2 non-class I-III mutations), and 29 (27.9%) harbored <em>BRAF</em> fusions. Eighteen patients received triple-targeted therapy, including prior EGFR-TKIs plus dabrafenib and trametinib, and 23 patients received other treatments. The median progression-free survival was significantly longer in patients receiving triple-targeted therapy than in those receiving other treatments (8.0 versus 2.5 months, <em>P</em> &lt; 0.001). Similar findings were observed in patients with <em>BRAF</em> mutations (9.0 versus 2.8 months, <em>P</em> = 0.004), particularly in those with <em>BRAF</em> class I mutations (9.0 versus 2.5 months, <em>P</em> &lt; 0.001). A potential benefit was also observed among patients with <em>BRAF</em> fusions (5.0 versus 2.0 months, <em>P</em> = 0.230). Twenty patients (48.8%) experienced adverse events. Dose reduction of RAF or MEK inhibitor was required in five patients (12.2%). Five patients (12.2%) permanently discontinued treatment (three on triple-targeted therapy; one on prior EGFR-TKI plus vemurafenib; one on prior EGFR-TKI plus trametinib).</div></div><div><h3>Conclusions</h3><div><em>BRAF</em> alterations, specifically <em>BRAF</em> mutations and <em>BRAF</em> fusions, facilitate resistance to EGFR-TKIs. Triple-targeted therapy is effective and safe for patients with <em>EGFR-</em>mutant NSCLC with acquired <em>BRAF</em> alterations, mainly among patients with <em>BRAF</em> class I mutations and potentially in patients with <em>BRAF</em> fusions.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103935"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)","authors":"M. Ueno ,&nbsp;C. Morizane ,&nbsp;M. Ikeda ,&nbsp;M. Ozaka ,&nbsp;F. Nagashima ,&nbsp;T. Kataoka ,&nbsp;J. Mizusawa ,&nbsp;A. Ohba ,&nbsp;S. Kobayashi ,&nbsp;H. Imaoka ,&nbsp;A. Kasuga ,&nbsp;N. Okano ,&nbsp;Y. Nagasaka ,&nbsp;M. Sasaki ,&nbsp;J. Furuse ,&nbsp;T. Okusaka","doi":"10.1016/j.esmoop.2024.103919","DOIUrl":"10.1016/j.esmoop.2024.103919","url":null,"abstract":"<div><h3>Background</h3><div>Although cisplatin plus gemcitabine and other combinations have improved the survival of advanced biliary tract cancer (BTC), high unmet medical needs remain. This study aimed to assess the efficacy and safety of nivolumab plus lenvatinib in the second-line treatment for advanced BTC.</div></div><div><h3>Patients and methods</h3><div>Nivolumab (240 mg) was administered biweekly. Phase I determined the recommended phase II dose of lenvatinib (20 mg or 14 mg). In phase II, the primary endpoint was the objective response rate (ORR). Secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The planned sample size was 32 patients with a power of 80%, a one-sided alpha error of 5%, threshold ORR of 10%, and expected ORR of 30%.</div></div><div><h3>Results</h3><div>In phase I, the recommended dose of lenvatinib was determined to be 20 mg in six patients, with one dose-limiting toxicity (myocarditis). In phase II, we enrolled 26 patients. ORR, DCR, and median OS and PFS were 9.4% [90% confidence interval (CI) 2.6% to 22.5%], 53.1% (95% CI 34.7% to 70.9%), and 6.4 months (95% CI 4.9-9.7 months) and 2.5 months (95% CI 1.5-4.1 months), respectively. No response was observed <em>in patients with</em> the usage of antibiotics. The grade 3 or 4 adverse events were hypertension (59.4%) and biliary tract infection (37.5%). Rash (28.1%) and hypothyroidism (21.9%) were observed as immune-mediated adverse events of any grade.</div></div><div><h3>Conclusions</h3><div>Nivolumab plus lenvatinib had a manageable safety in advanced BTC, but its efficacy in the second-line treatment was limited.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103919"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review","authors":"D. Prost ,&nbsp;S. Iseas ,&nbsp;M. Gatineau ,&nbsp;J. Adam ,&nbsp;S. Cavalieri ,&nbsp;C. Bergamini ,&nbsp;L. Licitra ,&nbsp;É. Raymond","doi":"10.1016/j.esmoop.2024.103722","DOIUrl":"10.1016/j.esmoop.2024.103722","url":null,"abstract":"<div><h3>Background</h3><div>Salivary gland cancers are infrequent and pose a challenge owing to their histological diversity and varied clinical behavior, making the selection of optimal systemic treatments for advanced or recurrent stages difficult. This systematic review aims to assess overall survival outcomes and systemic treatment responses across four types of salivary cancers.</div></div><div><h3>Methods</h3><div>A PubMed and Google Scholar search identified studies involving initially advanced or relapsed cases undergoing systemic treatment. Studies with clear, individualized data on treatment responses and outcomes were selected based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Of the 723 studies screened, 44 met our inclusion criteria.</div></div><div><h3>Results</h3><div>A total of 426 cases of recurrent/metastatic salivary gland cancer, mostly salivary duct carcinoma (SDC; <em>n</em> = 219) and adenoid cyst carcinoma (ACC; <em>n</em> = 167), were included. Histomolecular markers were heavily associated with histology, with <em>HER2</em> overexpression and androgen receptor nuclear expression typically found in SDC and adenocarcinoma not otherwise specified cases and KIT overexpression only in ACC. The response rates were associated with specific receptor blockage, with trastuzumab plus chemotherapy, and bicalutamide being the most effective (overall response rate 80% and 42.8%, respectively). Moreover, the response to treatment positively influenced overall survival (responders 38 versus non-responders 18.7 median months; <em>P</em> &lt; 0.001). In this retrospective analysis of a particular cohort, survival outcomes per histology types showed that anti-human epidermal growth factor receptor 2 therapy was more effective for SDC, while chemotherapy was more effective for ACC.</div></div><div><h3>Conclusion</h3><div>Systemic treatments contribute to the survival of patients with salivary gland cancer at relapsed or newly advanced stages. The response to treatment is heavily influenced by histological subtype and treatment specificity.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103722"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"58P NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine","authors":"P. Paliwal,&nbsp;V. Bhatia,&nbsp;S. Sharma,&nbsp;B. Bansal,&nbsp;S. K,&nbsp;A. Bhandari,&nbsp;S. Rana,&nbsp;S. Ahlawat","doi":"10.1016/j.esmoop.2024.103803","DOIUrl":"10.1016/j.esmoop.2024.103803","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103803"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology","authors":"C. Macarro ,&nbsp;P. Cresta Morgado ,&nbsp;S. Simonetti ,&nbsp;D. Navarro ,&nbsp;H. Alatoom ,&nbsp;C. Zatse ,&nbsp;D. Olmos ,&nbsp;P.G. Nuciforo ,&nbsp;A. Vivancos ,&nbsp;R. Olivera-Salguero ,&nbsp;T. Pascual ,&nbsp;J. Carles Galceran ,&nbsp;E. Castro ,&nbsp;J. Mateo ,&nbsp;R. Perez Lopez","doi":"10.1016/j.esmoop.2024.103748","DOIUrl":"10.1016/j.esmoop.2024.103748","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103748"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6P Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis","authors":"D. Arruda Navarro Albuquerque ,&nbsp;M. Trotta Vianna ,&nbsp;A. Vasiliu ,&nbsp;E.H. Cunha Neves Filho","doi":"10.1016/j.esmoop.2024.103752","DOIUrl":"10.1016/j.esmoop.2024.103752","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103752"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}